Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

PRIMO 2023 | Will neoadjuvant targeted therapies play a role in NSCLC?

Jorge Nieva, MD, University of California, San Francisco, CA, provides an overview of the potential role of targeted therapies in the neoadjuvant setting for non-small cell lung cancer (NSCLC). Trials such as the LCMC4 trial (NCT04712877) will evaluate targeted therapies, and Dr Nieva additionally highlights anecdotal evidence supporting the use of neoadjuvant targeted therapies. However, whether they will improve cure rate and their role in stage II/III lung cancer, remain unelucidated. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.